According to data published today in Lancet Oncology, a 14-year-long Swedish study has unequivocally demonstrated that PSA screening in men of 50 to 65 years of age does reduce the risk of prostate cancer-specific mortality — by about 50 percent.
Filed under: Diagnosis, Risk | Tagged: mortality, screening | 6 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
